trending Market Intelligence /marketintelligence/en/news-insights/trending/sUpwNfCPF-idwg6DTCKG2A2 content esgSubNav
In This List

Madrigal Pharmaceuticals prices common stock offering

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Madrigal Pharmaceuticals prices common stock offering

Madrigal Pharmaceuticals Inc. priced an underwritten registered public offering of 1,506,025 common shares at $83 apiece.

The company expects gross proceeds of about $125 million.

Madrigal granted underwriters a 30-day option to buy up to an additional 225,904 common shares.

The offering is expected to close by Dec. 21, subject to customary closing conditions.

Goldman Sachs & Co. LLC is acting as lead book-running manager for the offering, with Evercore ISI acting as book runner. JMP Securities, Roth Capital Partners and H.C. Wainwright & Co. are acting as co-managers for the offering.